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Abstract

Author Manuscript

Thiamine (Vitamin B1) is an essential nutrient and indispensable for normal growth and
development of the organism due to its multilateral participation in key biochemical and
physiological processes. Humans must obtain thiamine from their diet since it is synthesized only
in bacteria, fungi and plants. Thiamine deficiency (TD) can result from inadequate intake,
increased requirement, excessive deletion and chronic alcohol consumption. TD affects multiple
organ systems, including the cardiovascular, muscular, gastrointestinal, and central and peripheral
nervous systems. In the brain, TD causes a cascade of events including mild impairment of
oxidative metabolism, neuroinflammation and neurodegeneration, which are commonly observed
in neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and
Huntington’s disease (HD). Thiamine metabolites may serve as promising biomarkers for
neurodegenerative diseases and thiamine supplementations exhibit therapeutic potential for
patients of some neurodegenerative diseases. Experimental TD has been used to model agingrelated neurodegenerative diseases. However, to date, the cellular and molecular mechanisms
underlying TD-induced neurodegeneration are not clear. Recent research evidence indicates that
TD causes oxidative stress, endoplasmic reticulum (ER) stress and autophagy in the brain, which
are known to contribute to the pathogenesis of various neurodegenerative diseases. In this review,
we discuss the role of oxidative stress, ER stress and autophagy in TD-mediated
neurodegeneration. We propose that it is the interplay of oxidative stress, ER stress and autophagy
that contributes to TD-mediated neurodegeneration.
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Thiamine, also referred to as thiamin and vitamin B1, is a water-soluble and colorless
vitamin with a characteristic odor and slightly bitter taste [1]. Thiamine was first discovered
by two Dutch chemists, Dr. B. C. P. Jansen and his closest collaborator Dr. W. Donath in
1926, and it was isolated, purified and synthesized by Dr. R. R. Williams in 1936 [2].
Thiamine is an essential micronutrient for humans, which is supplied from a diet rich in
thiamine [3]. Thiamine is enriched in lean pork, beef, wheat germ and whole grains, organ
meats, eggs, fish, legumes, and nuts [4]. In humans, thiamine exists in 4 forms:
unphosphorylated thiamine, thiamine monophosphate, thiamine diphosphate, and thiamine
triphosphate [5]. Thiamine plays an essential role for life and health for humans since
thiamine derivatives and thiamine-dependent enzymes play a key role in cell metabolism [6,
7].
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Thiamine is a dicyclic compound with thiazole and aminopyrimidine rings joined by a
methylene bridge. Thiamine is absorbed into the body in the upper small intestine by two
transporters, THTR1 and THTR2, the products of the SLC19A2 and SLC19A3 genes,
respectively [8]. Thiamine diphosphate is also known as thiamine pyrophosphate (TPP),
which is the biologically active form of thiamine and serves as a cofactor for four major
enzyme systems: pyruvate dehydrogenase (EC 1.2.4.1) complex, an organized enzyme
assembly that connects glycolysis with the tricarboxylic acid (TCA) cycle; α-ketoglutarate
dehydrogenase (EC 1.2.4.2) complex (KGDHC), a multicomponent enzyme complex
associated with the TCA cycle; transketolase (EC 2.2.1.1), a key participant in the pentose
phosphate shunt involved in nucleic acid and lipid biosynthesis; and branched-chain alphaketoacid dehydrogenase (EC 1.2.4.4) complex which is required for the metabolism of
branched-chain amino acids [9]. Thiamine concentrations are measured either by direct
measurement via HPLC in plasma, whole blood, erythrocytes, or by determination of the
activity of a thiamine-dependent enzyme in erythrocytes called transketolase.

Author Manuscript

Thiamine deficiency (TD) can be caused by a variety of reasons, such as inadequate intake,
increased requirement, excessive loss, consumption of foods containing anti-thiamine
components, or a combination of these factors [10-12]. Decreased thiamine levels are
correlated with the aging process [13]. The recommended daily allowance for thiamine in
most countries is set at about 1.4 mg [14], while chronic alcohol consumption is the primary
cause of TD in the United States and other developed countries [15, 16]. Evidence suggests
that TD occurs in chronic alcoholics at a frequency of at least 25–31 % and up to 80 % [17].
TD adversely affects many organ systems including the cardiovascular [18], muscular [19],
gastrointestinal [20], and central and peripheral nervous systems [21]. The central nervous
system (CNS) is particularly sensitive to TD, because of its dependence on TPP-mediated
metabolic pathways involved in energy metabolism and neurotransmitter synthesis [22].
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Insufficient levels of thiamine causes neurological and metabolic disorders which may be
corrected by thiamine administration.
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TD disease remains a significant world health problem. Because thiamine is an important
cofactor involved in processes associated with the metabolism of lipids, glucose, amino
acids, and neurotransmitters, its deficiency can lead to severe complications in both the
nervous and cardiovascular systems. Generally, cardiac effects caused by TD are referred to
as wet beriberi, the peripheral neurological manifestations are called dry beriberi, and
delirium or mental confusion are termed Wernicke’s encephalopathy [23]. Beriberi was
thought of as a disease of the peripheral nervous system, heart, and muscles until the 1930s
when it was found that Wernicke’s encephalopathy was the acute cerebral manifestation of
severe thiamin deficiency[24]. In humans, the neurological disorder that is most clearly
associated with TD is Wernicke-Korsakoff syndrome (WKS), characterized by behavioral,
cognitive and neuropathological deficits [25]. Administration of thiamine is able to prevent,
reduce or reverse several symptoms in WKS patients, whereas some deficits persist
permanently [26]. TD is also implicated in several neurodegenerative diseases, such as
Alzheimer’s disease (AD), Parkinson’s disease(PD), and alcohol-induced dementia [27].
Therapeutic effects of thiamine supplementation have been observed in some
neurodegenerative diseases and alcohol-induced dementia [28-30]. In addition, accumulating
evidence has been documented that TD is able to cause regionally specific neuronal death in
animal and human brains which is accompanied with a mild chronic impairment of oxidative
metabolism [31-33]. TD also causes the activation of microglia, astrocytes and endothelial
cells [34] as well as abnormalities of cerebral glucose metabolism [35]. These features are
commonly observed in neurodegenerative diseases and make TD a feasible model to
investigate the mechanisms of neurodegeneration. Although TD-induced brain damages
have been well documented, the underlying cellular and molecular mechanisms are still
unclear.
Oxidative stress, endoplasmic reticulum (ER) stress and autophagy have been implicated in
pathogenesis of various neurodegenerative diseases, such as AD, PD, Huntington’s disease
(HD), and Amyotrophic Lateral Sclerosis (ALS) [36, 37]. Increasing evidence demonstrates
that TD also causes oxidative stress, ER stress and autophagy in the brain. In this review, we
discuss the recent progress in this line of research. We propose that it is the interplay of
oxidative stress, ER stress and autophagy that contributes to TD-mediated
neurodegeneration.

1. TD and neurodegeneration
Author Manuscript

Although many organ systems are affected by TD, the CNS is particularly vulnerable to TD.
This may be attributed to thiamine having lower levels in the human brain than in other
organs [38]. TPP, the main active form of thiamine, functions as an essential co-factor for a
number of thiamine-dependent enzymes, such as transketolase, pyruvate dehydrogenase
complex (PDHC), and α-ketoglutarate dehydrogenase complex (KGDHC). Once the levels
of thiamine are diminished in the human brain, the activity of these enzymes is affected,
leading to alterations in mitochondrial activity, impairment of oxidative metabolism,
decreased energy status and brain damage [39].

Mol Neurobiol. Author manuscript; available in PMC 2018 September 01.

Liu et al.

Page 4

Author Manuscript

TD is implicated in a number of neurodegenerative diseases and is also involved in alcohol
abuse-induced brain damages. WKS is a neuropsychiatric disorder caused by TD, which is
composed of two clinical stages. The acute stage, Wernicke’s encephalopathy, has
historically been associated with a classic triad of acute neurological symptoms: confusion,
ataxia, and ophthalmoplegia. The chronic stage, Korsakoff syndrome, follows those who
survive the acute stage and is a life-altering, permanent neuropsychiatric condition
characterized by anterograde and retrograde amnesia as well as frontal lobe dysfunction and
affective disturbance [40, 41]. The first observation showing the association between TD and
the etiology of WKS could be traced back to the 1930s [42]. It has now been established that
TD is the primary cause of WKS. Clinically, WKS is usually associated with chronic
alcoholism which depletes thiamine in the human body, but it can also be caused by
malnourishment [43, 44].
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AD is an age-related and progressive neurodegenerative disease characterized by the
deposition of β-amyloid senile plaques and tau-associated neurofibrillary tangles [45].
Patients with AD exhibit memory impairment and cognitive decline due to neuronal loss
mainly in the neocortex and the hippocampus [46]. AD currently affects over 36 million
people worldwide with an estimated global economic impact of approximately $605 billion
dollars in 2010 in addition to incalculable social and emotional burdens [47, 48]. Several
lines of evidence have shown an association between TD and AD. For example, plasma
thiamine levels were reduced in patients diagnosed with AD, suggesting that some AD
patients have TD [49]. In addition, one of the main features of AD is the severe reduction of
glucose metabolism in the brain of AD patients [50-52]. There are three thiamine-dependent
enzymes, including transketolase, PDHC, and KGDHC, which function at key steps of
glucose metabolism. It has been documented that the activities of these thiamine-dependent
enzymes were also diminished in AD brains [53-55]. Moreover, the reductions in thiaminedependent activity are associated with the severity of the dementia in AD patients [56]. In
animal models, TD increased the accumulation of beta-amyloid, exacerbates plaque
formation, promotes phosphorylation of tau and impairs memory, suggesting TD might play
a role in the pathology of AD [57, 58]. Treatment of benfotiamine, a thiamine derivative
with better bioavailability than thiamine, could reduce plaques, decrease phosphorylation of
tau and reverse memory deficits in a mouse model of AD [59]. However, in the clinical
trials, the therapeutic effects of thiamine supplementation are inconsistent in AD patients.
One report suggests that 3 to 8 g/day of thiamine administered orally have a mild beneficial
effect in dementia of AD [60]. On the contrary, some other studies indicate that there is no
significant improvement by thiamine supplementation in AD patients [61, 62]. Therefore,
the contribution of TD in the pathophysiology of AD remains to be clarified.

Author Manuscript

PD is the second most common form of neurodegeneration in the elderly population,
characterized by resting tremor, rigidity, slowness of movement, and postural imbalance
[63]. It affects more than 1% of individuals older than 55 years of age and more than 3% of
those older than 75 years of age [64]. The loss of dopaminergic neurons in the substantia
nigra is a major pathophysiological feature of patients with PD [65]. Several lines of
evidence have shown that thiamine or thiamine-dependent processes may be involved in the
pathogenesis of PD. For example, lower free thiamine levels in the cerebrospinal fluid were
found in PD patients in comparison to normal individuals, while levels of thiamineMol Neurobiol. Author manuscript; available in PMC 2018 September 01.
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derivatives, such as thiamine-diphosphate and thiamine-monophosphate, did not differ
significantly [66]. Additionally, the immunoreactivity of KGDHC, one of the most important
thiamine-dependent enzymes, was decreased in the substantia nigra of patients with PD, and
the reduction seemed correlated with the severity of degeneration [67, 68]. In some studies,
thiamine supplementation seemed to improve the outcomes for PD patients. For example,
administration of parenteral high-dose thiamine was effective in reversing motor and nonmotor symptoms in PD patients [28, 30]. These findings suggest that TD may be involved in
the pathophysiology of PD.
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It has been well established that chronic alcohol abuse causes both dementia and TD.
Chronic alcohol consumption can lead to at least two long-lasting neurological disorders
associated with severe cognitive dysfunction: alcohol-associated dementia (AAD) and WKS
[69]. For example, it has been estimated that greater than 10% of alcoholic patients have
symptoms of either AAD or WKS [70]. Wernicke's encephalopathy and Korsakoff's
psychosis in alcoholics are thought to be caused by TD. When the process goes untreated,
patients may develop alcohol-induced persisting dementia [27]. Poor dietary patterns, along
with the impact of alcohol consumption on absorption, storage, activation and excretion of
thiamine are thought to be the mechanisms for TD among alcohol-dependent individuals
[71].
Since TD is associated with various neurodegenerative diseases and shares many common
pathological features, experimental TD has been extensively used to investigate the
mechanisms of neurodegeneration [32, 72, 73].

2. Mechanisms underlying TD-mediated neurodegeneration
Author Manuscript

2.1. Oxidative stress
Oxidative stress is defined as disequilibrium between reactive oxygen species (ROS)
production and the ability to detoxify the reactive oxygen intermediates [74]. The brain is
particularly vulnerable to oxidative stress due to its high oxygen consumption and high
production of reactive oxygen and nitrogen species. Accumulating evidence has
demonstrated that oxidative stress plays an important role in excitotoxicity, axonal damage
and neuronal death [75], and is involved in the onset and progression of several
neurodegenerative diseases, such as AD, PD, HD, and ALS [76, 77].
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Like in neurodegenerative diseases, oxidative stress seems to play an important role in TDinduced brain damage. Both animal and cellular models have clearly shown that TD
increases ROS production and causes oxidative stress in the brain and neuronal cells. For
example, in TD animal model, a wide spectrum of markers of oxidative stress, such as heme
oxygenase-1, superoxide dismutase, ferritin, and malondialdehyde are increased in the brain
[32, 78, 79]. In addition, lipid peroxidation product, 4-hydroxynonenal (HNE), are also
increased in neurons of the CNS [80]. The changes in the levels of antioxidant enzymes,
lipid peroxidation, and protein carbonyl content in brain mitochondria have been reported in
the brains of TD animals [81]. Moreover, it has also been demonstrated that TD selectively
causes oxidative stress in neurons in vitro [58, 82].
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There are several mechanisms underlying TD-induced oxidative stress. One possible
mechanism might be due to mitochondrial dysfunction. Mitochondria are a major source of
ROS, and also a target of TD. Previous studies indicate that binding site densities for the
translocator protein, a useful marker of mitochondrial dysfunction, are increased in the
brains of TD animals [83]. TD may damage the antioxidant system in the brain. For
example, antioxidant enzymes such as superoxide dismutase, catalase, and glutathione
peroxidase are significantly reduced in the brain of TD animals. [81]. Another possible
mechanism is neuroinflammation which may contribute TD-induced CNS damage. TD
significantly increases pro-inflammatory cytokines, chemokines, interferons, as well as
many transcription factors known to control inflammatory gene expression are upregulated
in TD animals [33]. The neuroinflammation may alter mitochondrial membrane potential
and thus its function, resulting in an increase in ROS [84]. Reversely, oxidative stress can
also induce neuroinflammation. For example, there is increasing evidence that activated
microglia produce excessive ROS during aging and hypoxia, resulting in the nuclear factorκB-dependent excessive production of proinflammatory mediators, such as interleukin-1β,
tumor necrosis factor-α, and interleukin-6 [85].
2.2. ER stress
ER is the largest organelle found in the cells of eukaryotic organisms. It is an interconnected
network of membrane-enclosed tubules and sacs that extends from the nuclear membrane
throughout the cytoplasm. ER plays a critical role in a wide range of cellular processes. It
regulates protein folding, modification and transport. It also processes the synthesis and
distribution of phospholipids and steroids. ER is the site of calcium ion storage and regulates
intracellular calcium homeostasis [86, 87].
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Under physiologic conditions, there is a balance between ER protein load and folding
capacity. Alterations in ER homeostasis, such as increased protein synthesis, accumulation
of misfolded proteins, or alterations in the calcium or redox balance, lead to a condition
called ER stress [88]. The cellular adaptive response to cope with ER stress is known as the
unfolded protein response (UPR). Initially, the UPR functions to restore ER homeostasis by
increasing protein folding capacity and decreasing the accumulation of unfolded proteins.
Through a complex network, UPR acts to interrupt new protein translation, assist in proper
protein folding and promote the degradation of accumulated unfolded or misfolded proteins,
leading to a reduction of ER stress. If these mechanisms of adaptation and correction are
insufficient to restore ER homeostasis, ER stress is sustained, resulting in apoptotic cell
death [89, 90]. Therefore, UPR is generally considered a cellular defense mechanism.
During the UPR, three major UPR sensors, namely PERK (protein kinase RNA-like ER
kinase), IRE1 (inositol requiring protein-1), and ATF6 (activating transcription factor-6),
transduce information about the folding status of the ER to the cytosol and nucleus to restore
folding capacity [91, 92].
Neurodegenerative diseases, such as AD, PD, HD, ALS and prion-related diseases (PRD)
have in common the presence of protein aggregates in specific brain areas where significant
neuronal loss is detected. Emerging evidence suggests that ER stress may contribute to the
neurodegeneration in these neurodegenerative diseases [93]. For example, upregulation of
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UPR sensors has been observed in post mortem brain tissues and experimental models of
neurodegenerative diseases, such as AD, PD, HD, ALS and PRD [94, 95]. In experimental
models of neurodegenerative diseases, targeting UPR pathways appears beneficial for
alleviating neuronal loss[96]. We investigated the effect of TD on the ER with transmission
electron microscopy and showed that TD causes an abnormality in ER structure [97]. We
further demonstrated that TD up-regulates several markers of ER stress in the brain and
cultured neurons, such as GRP78, CHOP and the phosphorylation of eIF2α [97].
Furthermore, TD activates an ER stress-regulated caspase, caspase-12 and blocking the
caspase-12 activation significantly alleviates TD-induced neuronal death[97]. We have also
shown that TD activates double stranded RNA-activated protein kinase (PKR) which is also
believed to play an important role in ER stress [97, 98]. These findings suggest that ER
stress may underlie TD-induced damage to the CNS. To date, the mechanisms underlying
TD-induced ER stress is unclear. It has been well documented that oxidative stress and
disruption of calcium homeostasis can cause ER stress [99, 100]. TD is shown to cause
oxidative stress and the disruption of intracellular calcium concentration [97, 101].
Therefore, it is likely TD may induce ER stress through these mechanisms.
2.3. Autophagy
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Autophagy is a cellular catabolic process for the degradation of cytoplasmic components
within lysosomes [102, 103]. Autophagy plays a major role in the elimination of cellular
waste components, the renewal of intracellular proteins and the prevention of the build-up of
redundant or defective material [104]. There are three types of autophagy that are commonly
described, namely chaperone-mediated autophagy, microautophagy, and macroautophagy
and the latter being the major and best characterized subtype of autophagy [105]. Autophagy
consists of several sequential steps, including sequestration/formation of autophagosomes,
transportation to lysosomes, degradation, and recycling of degraded products [106].
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Autophagy is fundamental for the maintenance of homeostasis and especially important in
post-mitotic neuronal cells. Autophagy sequesters damaged and dysfunctional organelles/
protein, and transports them to lysosomes for degradation/recycling. This process provides
nutrients for injured neurons. Without competent autophagy, abnormal protein aggregates
accumulate, resulting in neurodegeneration, which is a common feature of
neurodegenerative diseases [107]. Recent studies have demonstrated that impairments of the
autophagic process are associated with several neurodegenerative diseases, such as AD, PD
and HD [108]. The deficiency of autophagic pathways documented in neurodegenerative
diseases is generally caused by three forms of dysregulations; these include insufficient
autophagy activation, autophagy dysfunction due to impaired lysosomal function, and
autophagic stress resulting from pathologic activation[109]. In general, autophagy is
neuroprotective and deficiency in autophagy may facilitate neurodegeneration. However,
dysregulated or excessive autophagy can also cause neuronal atrophy, neurite degeneration
and cell death [110]. Therefore, dependent on the specific situation and model system,
autophagy may have dual roles in both neuroprotection and neurodegeneration.
We investigated the effects of TD on the autophagy in the brain and cultured neurons. We
demonstrated that TD induces the accumulation of autophagosomes in neurons measured by
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transmission electron microscopy, and the up-regulation of autophagic markers LC3-II,
Atg5, and Beclin1 [73]. TD-induced expression of autophagic markers was reversed once
thiamine was re-administered. Inhibition of autophagy by wortmannin and Beclin1 siRNA
potentiates TD-induced death of neuronal cells. In contrast, activation of autophagy by
rapamycin alleviated neuronal cell death induced by TD in vitro and in the brain.
Intraperitoneal injection of rapamycin stimulates neuronal autophagy and attenuates TDinduced neuronal death and microglia activation in the submedial thalamus nucleus (SmTN)
[73]. These results suggest that autophagy is neuroprotective in response to TD-induced
neurodegeneration in the CNS. There are several potential mechanisms for TD-induced
autophagy. For example, TD is shown to affect mTOR and AMPK pathways which are
critical regulators of autophagy [73]. Additionally, TD may activate autophagy through the
induction of oxidative stress and/or ER stress because both oxidative stress and ER stress are
known to stimulate autophagy [111].
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2.4 Interplay among oxidative stress, ER stress and autophagy
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The recent research progress has clearly demonstrated that TD can activate oxidative stress,
ER stress and autophagy and the activation is associated with TD-induced
neurodegeneration. There is considerable interaction among oxidative stress, ER stress and
autophagy. For example, oxidative stress and ER stress are interconnected; usually oxidative
stress induces ER stress but sometimes ER stress can promote oxidative stress as well [112].
Both oxidative stress and ER stress may activate autophagy [111]. The interaction among
oxidative stress, ER stress and autophagy is complex; so is the contribution of their
interaction to TD-induced neurodegeneration. We propose a model of interaction of these
three components in the context of TD-induced neurodegeneration (Fig. 1). In this model,
TD first induces damages to the intracellular organelles which cause oxidative stress and ER
stress, resulting in neurodegeneration. TD-induced cellular injuries and/or oxidative stress
and ER stress activate autophagy which initially functions as a protective mechanism to
eliminate oxidative stress- or ER stress-induced cellular damage. Autophagy can also be
activated by TD through some key autophagy regulators, such as mTOR or AMPK. We have
recently demonstrated that the interplay among oxidative stress, ER stress and autophagy is
involved in ethanol-induced neurodegeneration [113]. Therefore, oxidative stress, ER stress
and autophagy are interconnected and interdependent processes. In normal neurons, the
homeostasis of these dynamic processes is well controlled and maintained. However, TD
disrupts the homeostasis, eventually causing neurodegeneration in the CNS.

3. Therapeutic implications
Author Manuscript

Experimental TD models offer an excellent opportunity to identify and evaluate therapeutic
approaches to alleviate neurodegeneration. These approaches are of potential clinical
significance for some neurodegenerative diseases. First, thiamine is able to across the bloodbrain barrier[114]. Thiamine supplementation has been used as a therapy for patients with
some neurodegenerative diseases. For example, thiamine (3-8 g/day) administered orally had
a mild beneficial effect in AD patients[60]. The injection of high doses of thiamine (100 mg)
parenterally twice a week was effective in reversing the symptoms of PD[28]. However, the
clinical outcomes are inconsistent. A careful re-evaluation of thiamine supplementation is
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therefore necessary. The dosage, combination with other nutrients and the route of thiamine
administration must be taken into careful consideration in clinical settings. Second, for
reducing oxidative stress, the antioxidants which have potent antioxidant properties while
having minimal side-effects should be evaluated. For example, natural antioxidants, such as
anthocyanins, curcumin and resveratrol are suitable for screening [115]. Third, many
compounds directly targeting the UPR and ER protein transportation system are under
investigation [116, 117]. These compounds are worthy to be evaluated in experimental TD
models because they may specifically eliminate ER stress and be beneficial to treat TDinduced ER stress and subsequent neurodegeneration with reduced side-effects. Fourth,
since the activation of autophagy appears protective against ethanol neurotoxicity,
pharmacological manipulation of autophagy should be considered a potential therapeutic
approach. The most well studied drug that induces autophagy is rapamycin, an MTORC1
inhibitor. Rapamycin is a FDA-approved drug and a widely used immune suppressor in
clinical transplant patients. Rapamycin and its analogs (CCI-779, RAD001 and AP23573)
have been used to activate autophagy in vitro and in vivo[118, 119]. We showed that
rapamycin alleviates TD-induced neurodegeneration [62]. In addition to directly targeting
MTOR, activation of autophagy by manipulating other pathways upstream of MTORC1,
such as AMPK, PI3K-AKT, GSK3B or TSC1/2 are alternative approaches. A number of
studies of chemical screening have identified chemicals and small molecule enhancers that
activate autophagy independent of MTOR, including some FDA approved drugs [119].
These compounds are also worthwhile to be evaluated in experimental TD models. Despite
the potential beneficial effects of autophagy in neurodegenerative diseases, excessive
autophagy may be detrimental and cause cell death. The experimental TD models offer a
good system to develop strategies for appropriate activation of autophagy.
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Conclusions
Decreased thiamine levels are associated with the aging process and TD causes
neurodegeneration. TD and some neurodegenerative diseases share many common features.
The mechanisms underlying TD-induced neurodegeneration, however, remain unclear. A
large body of recent research evidence indicates that TD can cause oxidative stress, ER
stress and autophagy in the brain. We propose that it is the interplay of oxidative stress, ER
stress and autophagy that contributes to TD-mediated neurodegeneration. Therefore,
therapeutic strategies simultaneously targeting oxidative stress, ER stress and autophagy
may provide more effective outcomes.
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ABBREVIATIONS
AD

Alzheimer’s disease

ALS

Amyotrophic lateral sclerosis
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ATF6

activating transcription factor-6

ER

endoplasmic reticulum

HD

Huntington’s disease

HNE

4-hydroxynonenal

IRE1

inositol requiring protein-1

KGDHC

α-ketoglutarate dehydrogenase complex

PD

Parkinson’s disease

PDHC

pyruvate dehydrogenase complex

PERK

protein kinase RNA-like ER kinase

PRD

prion-related diseases

ROS

reactive oxygen species

TD

thiamine deficiency

TPP

thiamine pyrophosphate

UPR

unfolded protein response

WKS

Wernicke-Korsakoff syndrome
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Figure 1.

The interplay of oxidative stress, ER stress and autophagy in TD-induced
neurodegeneration. TD induces oxidative stress and ER stress in the brain, which results in
neurodegeneration. Oxidative stress and ER stress can mutually regulate each other.
Oxidative stress and ER stress can activate autophagy. Autophagy is activated in response to
TD-induced neurotoxicity to alleviate oxidative stress and ER stress, therefore offering
protection against TD-induced neurodegeneration. It is the interplay of these processes that
contribute to the final outcomes of TD neurotoxicity.
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